Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Introduction: Previous research has demonstrated that tenofovir disoproxil fumarate (DF) is the most cost-effective nucleos(t)ide treatment for chronic hepatitis B (CHB) in the UK, Spain, Italy and France. However, to our knowledge, no published studies have yet evaluated the cost effectiveness of any treatments for CHB in a Canadian setting, where relative prices and management of CHB differ from those in Europe.
Aim: Our objective was to determine the cost effectiveness of tenofovir DF compared with other nucleos(t)ide therapies licensed for CHB in Canada from the perspective of publicly funded healthcare payers.
Methods: A Markov model was used to calculate the costs and benefits of nucleos(t)ide therapy in three groups of patients with hepatitis B e antigen (HBeAg)-positive and -negative CHB: nucleos(t)ide-naive patients without cirrhosis; nucleos(t)ide-naive patients with compensated cirrhosis; and lamivudine- resistant patients. Disease progression was modelled as annual transitions between 18 disease states. Transition probabilities, quality of life and costs were based on published studies. Health benefits were measured in QALYs. The reference year for costs was 2007 and costs and outcomes were discounted at 5% per annum.
Results: First-line tenofovir DF was the most effective nucleos(t)ide strategy for managing CHB, generating 6.85–9.39 QALYs per patient. First-line tenofovir DF was also the most cost-effective strategy in all patient subgroups investigated, costing between $Can43 758 and $Can48 015 per QALY gained compared with lamivudine then tenofovir. First-line tenofovir DF strongly dominated first-line entecavir. Giving tenofovir DF monotherapy immediately after lamivudine resistance developed was less costly and more effective than any other active treatment strategy investigated for lamivudine-resistant CHB, including second-line use of adefovir or adefovir + lamivudine. Probabilistic sensitivity analysis demonstrated 50% confidence that first-line tenofovir DF is the most cost-effective nucleos(t)ide strategy for treatmentnaive patients with CHB, at a $Can50 000 per QALY threshold, and confirmed that first-line tenofovir DF has the highest expected net benefits.
Conclusions: First-line tenofovir DF appears to be the most cost-effective nucleos(t)ide treatment for both cirrhotic and non-cirrhotic CHB patients in Canada, providing that society is willing to pay at least $Can48 015 per QALY gained, although sensitivity analyses highlighted uncertainty around the results.
- Fact sheet no. 204: hepatitis B. WHO, Geneva
- Wright, TL (2006) Introduction to chronic hepatitis B infection. Am J Gastroenterol 101: pp. 1-6 CrossRef
- Sherman, M, Shafran, S, Burak, K (2007) Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol 21: pp. 5-24
- Hoffmann-La Roche Limited. Product monograph: pegasys peginterferon alfa-2a injection (pre-filled syringes: 180 mcg/0.5 mL, single use vials 180 mcg/1 mL) [online]. Available from URL: http://www.rochecanada.com/gear/glossary/servlet/staticfilesServlet?type=data&communityId=re753001&id=static/attachedfile/re7300002/re77300002/AttachedFile_08765.pdf [Accessed 2011 Sep 7]
- Marcellin, P, Lau, GK, Bonino, F (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351: pp. 1206-17 CrossRef
- Wong, DK, Cheung, AM, Rourke, K (1993) Effect of alphainterferon treatment in patients with hepatitis B e antigenpositive chronic hepatitis B: a meta-analysis. Ann Intern Med 119: pp. 312-23
- EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50: pp. 227-42 CrossRef
- Lai, CL, Dienstag, J, Schiff, E (2003) Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36: pp. 687-96 CrossRef
- Lok, AS, Lai, CL, Leung, N (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125: pp. 1714-22 CrossRef
- Snow-Lampart, A, Chappell, B, Curtis, M (2008) Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomised to receive tenofovir DF 300 mg QD [poster]. The 59th Annual Meeting of the American Association for the Study of Liver Disease.
- Khungar, V, Han, SH (2010) A systematic review of side effects of nucleoside and nucleotide drugs used for treatment of chronic hepatitis B. Curr Hepat Rep 9: pp. 75-90 CrossRef
- Tenney, DJ, Rose, RE, Baldick, CJ (2009) Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49: pp. 1503-14 CrossRef
- Hadziyannis, SJ, Tassopoulos, NC, Heathcote, EJ (2006) Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years. Gastroenterology 131: pp. 1743-51 CrossRef
- Dakin, H, Fidler, C, Harper, C (2010) Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of chronic hepatitis B. Value Health 13: pp. 934-45 CrossRef
- Chang, TT, Gish, RG, Man, R (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: pp. 1001-10 CrossRef
- Bristol-Myers Squibb Pharmaceuticals Ltd. Entecavir (baraclude®) for the treatment of chronic hepatitis B single technology appraisal submission to the National Institute forHealth and Clinical Excellence. NICE, London
- Marcellin, P, Heathcote, EJ, Buti, M (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Eng J Med 359: pp. 2442-55 CrossRef
- Ontario Drug Benefit. eFormulary. Prices effective 2008 Aug 28 [online]. Available from URL: http://www.healthinfo.moh.gov.on.ca/formulary/index.jsp [Accessed 2008 Sep 17]
- RAMQ formulary. 17th ed. 2008 Jun 2 [online]. Available from URL: http://www.prod.ramq.gouv.qc.ca/DPI/PO/Commun/PDF/Liste_Med/Liste_Med/liste_med_2008_06_02_en.pdf [Accessed 2011 Sep 6]
- Woo, G, Tomlinson, G, Nishikawa, Y (2010) Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian metaanalyses. Gastroenterology 139: pp. 1218-29 CrossRef
- Dakin, H, Bentley, A, Dusheiko, G (2010) Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health 13: pp. 922-33 CrossRef
- Buti, M, Brosa, M, Casado, MA (2009) Modeling the costeffectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 51: pp. 640-6 CrossRef
- Deniz, B, Buti, M, Brosa, M (2008) Cost-effectiveness simulation analysis of tenofovir disoproxil fumarate (tenofovir), lamivudine, adefovir dipivoxil (adefovir) and entecavir of HBeAg negative (-) patients with chronic hepatitis-B (CHB) in Spain [abstract 557]. J Hepatol 48Suppl.: pp. 209 CrossRef
- Deniz, B, Everhard, F (2008) Cost-effectiveness simulation analysis of tenofovir disoproxil fumarate (tenofovir) in HBeAg negative (-) patients with chronic hepatitis-B (CHB) in Italy and France [abstract 559]. J Hepatol 48Suppl.: pp. 210 CrossRef
- Product monograph: hepsera® adefovir dipivoxil tablets (10 mg). Antiviral agent. Date of revision: 2009 May 25. Foster City (CA): Gilead Sciences, Inc. [online]. Available from URL: http://www.gilead.ca/pdf/ca/hepsera_pm_english.pdf [Accessed 2010 Jun 17]
- Baraclude® (entecavir) tablets 0.5 mg, oral solution 0.05 mg/mL. Antiviral: product monograph. Bristol-Myers Squibb Canada [online]. Available from URL: http://www.bmscanada.ca/static/products/en/pm_pdf/Baraclude_E_19%20Nov%202010_PM_DIST_CLN.pdf [Accessed 2011 Sep 6]
- Viread® (tenofovir disoproxil fumarate tablets) 300 mg antiretroviral agent: product monograph. Gilead Sciences, Inc. [online]. Available from URL: http://www.gilead.ca/pdf/ca/viread_pm_english.pdf [Accessed 2011 Sep 6]
- CEDAC final recommendation on reconsideration and reasons for recommendation: tenofovir (Viread® - Gilead Sciences Canda, Inc.
- CEDAC final recommendation and reasons for recommendation: tenofovir/emtricitabine/efavirenz (Atripla ™- Bristol-Myers Squibb Canada andGilead Sciences Canada, Inc.).
- Fung, SK, Wong, FS, Wong, DK (2006) Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. Liver Int 26: pp. 796-804 CrossRef
- Gagnon, YM, Levy, AR, Iloeje, UH (2004) Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol 38: pp. 179-86 CrossRef
- Levy, AR, Kowdley, KV, Iloeje, U (2008) The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 11: pp. 527-38 CrossRef
- Franchis, R, Hadengue, A, Lau, G (2003) EASL International Consensus Conference on Hepatitis B. J Hepatol 39: pp. 3-25
- Fung, SK, Mazzulli, T, El-Kashab, M (2008) Lamivudineresistant mutation detected among treatment-naive hepatitis B patients is common and may be associated with treatment failure [poster]. 59th Annual meeting of the American Association for the Study of Liver Disease.
- Statistics Canada. Table 102-0218: life expectancy, abridged life table, by age group and sex, three-year average, Canada, provinces, territories, health regions and peer groups, occasional (years) [online]. Available from URL: http://www5.statcan.gc.ca/cansim/a05?id=1020218&pattern=Life+expectancy%2C+abridged+life+table&stByVal=1&paSer=&lang=eng [Accessed 2011 Sep 6]
- Guidelines for the economic evaluation of health technologies: Canada. CADTH, Ottawa (ON)
- CEDAC final recommendation on reconsideration and reasons for recommendation: telbivudine (Sebivo™ - Novartis Pharmaceuticals Canada Inc.).
- CEDAC final recommendation on reconsideration and reasons for recommendation: entecavir (baraclude™ - Bristol-Myers Squibb Canada).
- Gilead Sciences. Study GS-US-174-0106 week 48 clinical study report: tenofovir disoproxil fumarate (DF and emtricitabine/ tenofovir DF fixed-dose combination). Data on file, 2008
- Berg, T, Marcellin, P, Zoulim, F (2010) Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 139: pp. 1207-17 CrossRef
- Bommel, F, Zollner, B, Sarrazin, C (2006) Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44: pp. 318-25 CrossRef
- Buti, M, Hadziyannis, S, Mathurin, P (2008) Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis [podium presentation #1352]. 43rd Annual Meeting of the European Association for the Study of the Liver.
- Crowley, S, Tognarini, D, Desmond, P (2002) Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 17: pp. 153-64 CrossRef
- Crowley, SJ, Tognarini, D, Desmond, PV (2000) Costeffectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 17: pp. 409-27 CrossRef
- Fattovich, G, Brollo, L, Giustina, G (1991) Natural history and prognostic factors for chronic hepatitis type B. Gut 32: pp. 294-8 CrossRef
- Liaw, YF, Tai, DI, Chu, CM (1988) The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8: pp. 493-6 CrossRef
- Sung, JJ, Lai, JY, Zeuzem, S (2008) Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 48: pp. 728-35 CrossRef
- Lai, CL, Leung, N, Teo, EK (2005) A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129: pp. 528-36
- Heathcote, J, George, J, Gordon, S (2008) Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103). 43rd Annual Meeting of the European Association for the Study of the Liver.
- Reijnders, JG, Pas, SD, Schutten, M (2009) Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 50: pp. 674-83 CrossRef
- Kind, P, Hardman, G, Macran, S (1999) UK population norms for EQ-5D. York: Centre for Health Economics.
- Wong, JB, Koff, RS, Tine, F (1995) Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 122: pp. 664-75
- Statistics Canada. Table 326-0021. Consumer price index (CPI), 2005 basket, annual (2002=100 unless otherwise noted), CANSIMdatabase. Based on Canadian geographical region and healthcare commodity group [online]. Available from URL: http://www5.statcan.gc.ca/cansim/pick-choisir?lang=eng&searchTypeByValue=1&id=3260021 [Accessed 2011 Sep 6]
- Zethraeus, N, Johannesson, M, Jonsson, B (2003) Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics 21: pp. 39-48 CrossRef
- Stinnett, AA, Mullahy, J (1998) Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 18: pp. 68-80 CrossRef
- McGuire, A Chapter 1: theoretical concepts in the economic evaluation of health care. In: Drummond, M, McGuire, A eds. (2001) Economic evaluation in health care: merging theory with practice. Oxford University Press, Oxford
- Briggs, AH (2000) Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17: pp. 479-500 CrossRef
- Briggs, AH, Goeree, R, Blackhouse, G (2002) Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 22: pp. 290-308
- Claxton, K (1999) The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 18: pp. 341-64 CrossRef
- Kamal, A, Gerson, L, Ahmed, A (2007) Cost-effectiveness of new treatment paradigms for e-Ag negative chronic hepatitis B [abstract no. 987]. 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
- Kanwal, F, Gralnek, IM, Martin, P (2005) Treatment alternatives for chronic hepatitis B virus infection: a costeffectiveness analysis. Ann Intern Med 142: pp. 821-31
- Shepherd, J, Jones, J, Takeda, A (2006) Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 10: pp. 1-183
- Lai, CL, Gane, E, Liaw, YF (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357: pp. 2576-88 CrossRef
- Drummond, MF, Brien, B, Stoddart, GL (1997) Methods for the economic evaluation of health care programmes. Oxford Medical Publications, Oxford
- Guide to the methods of technology appraisal. NICE, London
- Minuk, G, Uhanova, J (2001) Chronic hepatitis B infection in Canada. Can J Infect Dis 12: pp. 351-6
- Gish, RG, Gadano, AC (2006) Chronic hepatitis B: current epidemiology in the Americas and implications formanagement. J Viral Hepat 13: pp. 787-98 CrossRef
- Zhang, J, Zou, S, Giulivi, A (2001) Epidemiology of hepatitis B in Canada. Can J Infect Dis 12: pp. 345-50
- Yang, H, Qi, X, Sabogal, A (2005) Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 10: pp. 625-33
- Prescribing information: Sebivo® (telbivudine). Tablets (film-coated) 600 mg. Antiviral agent. Novartis Pharmaceuticals Canada Inc, Dorval (QC)
- Dore, GJ, Cooper, DA, Pozniak, AL (2004) Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 189: pp. 1185-92 CrossRef
- Curtis, M, Harris, J, Borroto Esoda, K (2008) Tenofovir is equally active in vitro against wild-type HBV clinical isolates of genotypes A-H [abstract]. Hepatology 48: pp. 735
- Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective
Volume 29, Issue 12 , pp 1075-1091
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Abacus International, 6 Talisman Road, Bicester, Oxfordshire, OX26 6HR, UK
- 2. Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford, UK
- 3. Department of Medicine, University of Toronto and University Health Network, Toronto, ON, Canada